Overview
UK specialty chemicals firm's 2025 sales meets analyst expectations
Adjusted operating profit for 2025 beat analyst expectations
Outlook
Croda expects 2026 organic sales growth within 3-6% range
Company anticipates increased adjusted operating margin in 2026
Croda's 2026 adjusted operating profit to align with market expectations
Result Drivers
CONSUMER CARE AND LIFE SCIENCES - Growth in these segments drove sales, with Consumer Care up 7.9% and Life Sciences up 7.7% at constant currency
INNOVATION AND CUSTOMER CO-CREATION - Focus on innovation and customer projects led to 10% increase in new product sales
TRANSFORMATION PROGRAM - Program aimed at enhancing growth and efficiency contributed to performance improvements
Company press release: ID:nRSX0805Ua
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Meet
GBP 1.699 bln
GBP 1.69 bln (14 Analysts)
FY Adjusted Operating Profit
Beat
GBP 295.3 mln
GBP 286.15 mln (14 Analysts)
FY Pretax Profit
GBP 91 mln
FY Adjusted Pretax Profit
GBP 276.2 mln
FY Dividend
GBP 1.11
FY Operating Profit
GBP 110.1 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy."
Wall Street's median 12-month price target for Croda International PLC is GBp3,075.00, about 3% above its February 23 closing price of GBp2,985.00
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)